Chemoinformaics analysis of 5,8,11-eicosatriynoic acid
| Molecular Weight | 300.442 | nRot | 9 |
| Heavy Atom Molecular Weight | 272.218 | nRig | 4 |
| Exact Molecular Weight | 300.209 | nRing | 0 |
| Solubility: LogS | -4.918 | nHRing | 0 |
| Solubility: LogP | 4.9 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 50 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 28 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 53.6742 |
| nHD | 1 | BPOL | 28.9578 |
| QED | 0.491 |
| Synth | 3.06 |
| Natural Product Likeliness | 0.867 |
| NR-PPAR-gamma | 0.981 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.96 |
| Pgp-sub | 0 |
| HIA | 0.604 |
| CACO-2 | -4.802 |
| MDCK | 0.0000113 |
| BBB | 0.07 |
| PPB | 0.925571 |
| VDSS | -0.164 |
| FU | 0.00136555 |
| CYP1A2-inh | 0.817 |
| CYP1A2-sub | 0.159 |
| CYP2c19-inh | 0.896 |
| CYP2c19-sub | 0.377 |
| CYP2c9-inh | 0.717 |
| CYP2c9-sub | 0.994 |
| CYP2d6-inh | 0.216 |
| CYP2d6-sub | 0.124 |
| CYP3a4-inh | 0.487 |
| CYP3a4-sub | 0.023 |
| CL | 8.542 |
| T12 | 0.753 |
| hERG | 0 |
| Ames | 0.01 |
| ROA | 0.239 |
| SkinSen | 0.973 |
| Carcinogencity | 0.573 |
| EI | 0.983 |
| Respiratory | 0.972 |
| NR-Aromatase | 0.114 |
| Antiviral | Yes |
| Prediction | 0.536672 |